2025-01-24 10:44Revenue Projections - The estimated revenue for 2024 is projected to be between RMB 600 million and RMB 700 million, representing a decline of 19% to 5% compared to RMB 738.4 million in the previous year[3]. Profit Expectations - The net profit attributable to shareholders is expected to be between RMB 38 million and RMB 57 million, a decrease of 81% to 72% from RMB 202.5 million in the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between RMB 83 million and RMB 100 million, down 44% to 32% from RMB 147.7 million in the previous year[3]. - The significant decrease in non-recurring gains and losses is expected to impact the net profit, with a reduction of approximately RMB 99.8 million compared to the previous year[6]. Order and Market Position - The company secured new orders worth between RMB 9.5 billion and RMB 10.5 billion, showing growth compared to RMB 7.85 billion in the previous year[8]. - The net new orders for 2024 are estimated to be between RMB 8.4 billion and RMB 8.9 billion, an increase from RMB 7.85 billion in 2023[8]. - The company continues to hold the leading position in China's clinical research outsourcing industry, maintaining the highest market share according to data from the Ministry of Science and Technology[8]. Challenges and Risks - The company faces competitive pressure and growth challenges in its main business due to the cancellation of some existing orders and cash flow issues among clients[8]. - The financial income from large time deposits has decreased by approximately RMB 140 million due to changes in bank interest rules, impacting overall financial performance[9]. - The company emphasizes the importance of monitoring industry trends and conducting risk assessments to manage financial and operational risks effectively[6].